A clinical study of NTRC 12026-0 for Haematological malignancies
Latest Information Update: 09 Oct 2023
At a glance
- Drugs NTRC-12026-0 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; First in man
Most Recent Events
- 09 Oct 2023 New trial record
- 11 Sep 2023 According to Crossfire Oncology media release, the study to be initiated by H2 2024.